Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature

You, Yongfei; Wang, Panpan; Wei, Xi; Xu, Liping; Gong, Yi; Zhang, Weihua

doi:10.2147/ott.s304900

Cited by 5 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various selective immunotherapeutic and chemotherapeutic approaches including AR inhibitors, anti-Her2 targeted therapy, and androgen deprivation therapy applied in recent years have shown mixed results. [57][58][59] With some exceptions, specific cytopathologic features as described by others were largely present in this series. Common to nearly all prior cytologic and histopathologic descriptions and evident in our aspirates was the presence of large cells in aggregates, and as single forms possessing moderate to sometimes abundant finely granular cytoplasm.…”

Section: Discussionsupporting

confidence: 53%

See 1 more Smart Citation

Salivary duct carcinoma: A report of 70 FNA cases and review of the literature

Wakely

2022

Cancer Cytopathology

View full text Add to dashboard Cite

BACKGROUND:Although usually recognized as malignant, fine-needle aspiration (FNA) biopsy of salivary duct carcinoma (SDC) has been confused with other primary salivary gland (SG) neoplasms. This article undertook an analysis of a large collection of SDC FNA cases to assess diagnostic accuracy, specificity, and cytopathology. METHODS: Cytopathology files were searched for SDC with histopathologic validation. FNA biopsy smears were performed using standard techniques. RESULTS:Seventy cases from 56 patients (M:F, 1.9:1; age range, 26-92 years; mean age, 65 years) met inclusion criteria. All had tissue confirmation of SDC. FNA sites included: parotid gland (42, 60% cases), neck (10), submandibular gland (7), pre-/ post-auricular area (5), face/cheek (3), mediastinal lymph nodes (2), and clavicle (1). Aspirates were from primary (52, 74%), metastatic (12, 17%), and locally recurrent (6, 9%) neoplasms. FNA diagnoses included: SDC (19, 27%), favor/suspicious for SDC (7, 10%), high-grade carcinoma (11), adenocarcinoma ( 9), carcinoma ( 6), malignant (6), SG neoplasm (5), atypia (3), SDC versus another malignancy (2), and pleomorphic adenoma (2). Large polygonal cells in groups and single forms showed cribriforming, variable necrosis, pseudopapillae, and oncocytic change. Androgen receptor staining was positive in all cases.CONCLUSIONS: FNA biopsy is accurate and reliable in classifying SDC as a malignant neoplasm, but much less so for identification as a specific tumor type. Using the Milan system, 86% of aspirates were classified as either malignant or suspicious for malignancy. A recurring pitfall includes sampling error in cases of SDC ex pleomorphic adenoma. Cancer Cytopathol 2022;130:595-608.

show abstract

Section: Discussionsupporting

confidence: 53%

“…Frequent PIK3CA/HRAS co‐mutations may be a potential cause of anti‐HER2 resistance. Various selective immunotherapeutic and chemotherapeutic approaches including AR inhibitors, anti‐Her2 targeted therapy, and androgen deprivation therapy applied in recent years have shown mixed results 57‐59 …”

Section: Discussionmentioning

confidence: 99%

Salivary duct carcinoma: A report of 70 FNA cases and review of the literature

Wakely

2022

Cancer Cytopathology

View full text Add to dashboard Cite

show abstract

“…In published data, a dose reduction because of toxicity was required in six patients (46%) receiving tipifarnib (4 because of cytopenia, 2 because of reversible renal failures), hypoglycemia requiring dose reduction was reported for alpelisib ( 9 , 21 ). Toxicity data were not reported in the literature for patients receiving antiandrogen therapy in this cohort ( 22 , 23 ). Available data from combined ADT in SGC reported no CTCAE grade 4/5 events and discontinuation of part of the combined ADT due to adverse events in 2 out of 36 patients ( 10 ).…”

Section: Resultsmentioning

confidence: 91%

Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma

et al. 2023

View full text Add to dashboard Cite

Background and purposeA subgroup of salivary duct carcinoma (SDC) harbor overexpression of the androgen receptor (AR), and co-occurring mutations in the HRAS- and PIK3CA-genes. The impact of genomic complexity on targeted treatment strategies in advanced cancer is unknown.Materials and methodsWe analyzed molecular and clinical data from an institutional molecular tumor board (MTB) to identify AR+, HRAS/PIK3CA co-mutated SDC. Follow-up was performed within the MTB registrational study or retrospective chart review after approval by the local ethics committee. Response was assessed by the investigator. A systematic literature search was performed in MEDLINE to identify additional clinically annotated cases.Results4 patients with AR+ HRAS/PIK3CA co-mutated SDC and clinical follow-up data were identified from the MTB. An additional 9 patients with clinical follow-up were identified from the literature. In addition to AR overexpression and HRAS and PIK3CA-alterations, PD-L1 expression and Tumor Mutational Burden > 10 Mutations per Megabase were identified as additional potentially targetable alterations. Among evaluable patients, androgen deprivation therapy (ADT) was initiated in 7 patients (1 Partial Response (PR), 2 Stable Disease (SD), 3 Progressive Disease (PD), 2 not evaluable), tipifarnib was initiated in 6 patients (1 PR, 4 SD, 1 PD). One patient each was treated with immune checkpoint inhibition (Mixed Response) and combination therapies of tipifarnib and ADT (SD) and alpelisib and ADT (PR).ConclusionAvailable data further support comprehensive molecular profiling of SDC. Combination therapies, PI3K-inhibitors and immune therapy warrant further investigation, ideally in clinical trials. Future research should consider this rare subgroup of SDC.

show abstract

“…It was first described in 1968 by Kleinsasser et al 2 . This rare and aggressive tumor has 21 primary subtypes defined by the World Health Organization 3 . SDC accounts for 0.2-9% of salivary gland tumors 4 .…”

Section: Introductionmentioning

confidence: 99%

“…Clinically, SDC is quite aggressive and typically patients present with a rapidly growing painful mass that often involves the facial nerve 6 . SDC treatment; includes total parotidectomy and ipsilateral neck dissection, followed by adjuvant chemo-radiotherapy or postoperative radiotherapy and targeted therapies 3 . However, the prognosis of SDC is poor and the mortality rate of the cases within 5 years is 60% 4 .…”

Section: Introductionmentioning

confidence: 99%

Salivary Gland Ductal Carcinoma of Accessory Parotid Gland

BORA,

GÖKSU,

KOÇ

2023

CMJ

View full text Add to dashboard Cite

Salivary gland ductal carcinoma (SDC) is a rare, aggressive tumor with a highly malignant course and originates most frequently from the parotid gland among the major salivary glands. The incidence of accessory parotid gland (APG) varies between 21-56% and the incidence of tumor in APG is 1-8% of all parotid tumors. SDC is rarely seen in accessory glands. It was aimed to present our case, which was diagnosed with SDC in APG, in the light of the literature.

show abstract

Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature

Cited by 5 publications

References 27 publications

Salivary duct carcinoma: A report of 70 FNA cases and review of the literature

Salivary duct carcinoma: A report of 70 FNA cases and review of the literature

Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma

Salivary Gland Ductal Carcinoma of Accessory Parotid Gland

Contact Info

Product

Resources

About